Anti-idiotype antibody vaccine therapy for cancer

Bibliography

• WIGLE WO: The immune response of rabbits tolerant to bovine serum albumin to the injection of other heterologous serum albumins. I Exp. Med. (1961) 114:111–125.
   PubMed Web of Science ®Google Scholar
• JERNE NK: Towards a network theory of the immune system. Ann. InonunoL Paris (1974) 125C:373–389.
   PubMed Web of Science ®Google Scholar
• ••Jerne pointed out the physiologicalsignificance of internal image anti-Id antibodies which, in a way, link the universe of foreign antigens with the self antigens.
   Google Scholar
• LINDEMANN J: Speculations on idiotypes of homobodies. Ann. bronunol Paris (1973) 124:171–184.
   PubMedGoogle Scholar
• ••Certain anti-Id antibodies carry the internal image of antigens because their idiotypes cross react with antigen. Lindemann called these antibodies homobodies.
   Google Scholar
• BHATTACHARYA-CHATTERJEE M,KOHLER H: Anti-idiotype tumor vaccines. Adv. Exp. Med. Biol. (1990) 251:113–128.
   Google Scholar
• •A comprehensive review of anti-Id vaccines against bacterial, viral and parasitic infections as well as tumours.
   Google Scholar
• BROCK R, WIESMULLER KH, JUNG G, WALDEN P: Molecular basis for the recognition of two structurally different major histocompatibility complex/peptide complexes by a single T-cell receptor. Proc. NatL Acad. Sci. (1996) 93:13108–13113.
   PubMed Web of Science ®Google Scholar
• LOFTUS DJ, CHEN Y, COVELL DG, ENGELHARD VH, APPELLA E: Differential contact of disparate Class I/ peptide complexes as the basis for epitope cross-recognition by a single T cell receptor.InonunoL (1997) 158:3651–3658.
   Google Scholar
• DESAI, SA, WANG X, NORONHA EJ et al.: Structural relatedness of distinctdeterminants recognized by mAb TP25.99 on 132-microglobulin-associated and 132_ microglobulin-free HLA class I heavy chains.' Innnunol (2000) 165:3275–3283.
   Google Scholar
• ••Results suggest that a conformational anda linear peptide derived from an antigen may express the same determinant, in spite of the lack of amino acid sequence homology.
   Google Scholar
• RUIZ PJ, WOLKOWICZ R, WAISMAN A et al.: Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nat. Med. (1998) 4:710–712.
   PubMed Web of Science ®Google Scholar
• •Results suggest the role of idiotypic immunisation in the production of antianti-Id Ab3 and cytotoxic T cell responses which protect mice from tumour challenge.
   Google Scholar
• RAYCHAUDHURI S, SAEKI Y, CHEN JJ, KOHLER H: Tumor-specific idiotype vaccine. IV. Analysis of the idiotypic network in tumor immunity.bronunol (1987) 139:3902–3910
   Google Scholar
• DURRANT LG, BUCKLEY DJ, ROBINS RA, SPENDLOVE I: 105AD7cancer vaccine stimulates anti-tumor helper and cytotoxic T cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses. Int.' Cancer (2000) 85:87–92.
   PubMed Web of Science ®Google Scholar
• ••Results suggest that multiple immunisations with anti-Id are required to generate CD4 and CD8 memory T cell responses.
   Google Scholar
• PRIDE MW, SHUEY S, GRILLO-LOPEZ A et al.: Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen. Clin. Cancer Res. (1998) 4:2363–2370.
   PubMed Web of Science ®Google Scholar
• ••Anti-Id immunisation induced HLA-A2restricted CTL response in patients which was correlated with survival prolongation.
   Google Scholar
• WAGNER U, KOHLER S, REINARTZ S et al.: Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA 125: immune response and survival in palliative treatment. Clin. Cancer Res. (2001) 7:1154–1162.
   PubMed Web of Science ®Google Scholar
• SUGAI S, PALMER DW, TALAL N, WITZ IP: Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW Fl mice. I Exp. Med. (1974) 140:1547–1558.
   PubMedGoogle Scholar
• CHEN JJ, SAEKI Y, SHI L, KOHLER H:Synergistic anti-tumor effects with combined 'internal image' anti-idiotypes and chemotherapy. Innnunol (1989) 143:1053–1057.
   Google Scholar
• KENNEDY RC, DREESMAN GR, BUTEL JS, LANFORD RE: Suppression of in vivo tumor formation induced by simian virus 40-transformed cells in mice receiving anti-idiotypic antibodies. I Exp. Med. (1985) 161:1432–1439.
   PubMed Web of Science ®Google Scholar
• NELSON KA, GEORGE E,SWENSON C, FORSTROM JW, HELLSTROM KE: Immunotherapy of murine sarcomas with auto-anti-idiotypic monoclonal antibodies which bind to tumor-specific T cells. Innnunol (1987) 139:2110–2117.
   Google Scholar
• PERVIN S, CHAKRABORTY M, BHATTACHARYA-CHATTERJEE M, ZEYTIN H, FOON KA,CHATTERJEE S: Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen.Cancer Res. (1997) 57:728–734.
   PubMedGoogle Scholar
• ••Results suggest that anti-Id CeaVac was protective and therapeutic in a murine model for human carcinoembryonic antigen.
   Google Scholar
• HERLYN D, ROSS AH, KOPROWSKI H: Anti-idiotypic antibodies bear the internal image of a human tumor antigen. Science (1986) 232:100–102.
   PubMed Web of Science ®Google Scholar
• KOIDO T, SCHECK S, HERLYN D: Induction of immunity to colon carcinoma antigen C017-1A by monoclonal anti-idiotype (Ab2): effects of Ab2 fragmentation, carrier and adjuvant. Tumor Targeting (1995) 1:115–124.
   Google Scholar
• RIETHMULLER G, HOLZ E, SCHLIMOK Get al.: Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. j Clin. Onc. (1998) 16:1788–1794.
   Google Scholar
• FAGERBERG J, STEINMETZ M, WIGZELL H, ASKELOF P, MELLSTEDT H: Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc. NatL Acad. Sd. USA (1995) 92:4773–4777.
   PubMed Web of Science ®Google Scholar
• •Anti-Id immunisation induced both antibody and CD4 T cell response in this group of colorectal cancer patients.
   Google Scholar
• SOMASUNDARAM R, ZALOUDIK J, LUTZ J et aL: Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody.Immunol (1995) 155:3253–3261.
   Web of Science ®Google Scholar
• DURRANT LG, DORAN M, AUSTIN EB, ROBINS RA: Induction of cellular immune responses by a murine monoclonal anti-idiotypic antibody recognizing the 791Tgp72 antigen expressed on colorectal, gastric and ovarian human tumors. Int. J. Cancer (1995) 61:62–66.
   PubMed Web of Science ®Google Scholar
• DENTON GWL, DURRANT LG, HARDCASTLE JD, AUSTIN EB, SEWELL HF, ROBINS RA: Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. hat. J. Cancer (1994) 57:10–17.
   PubMed Web of Science ®Google Scholar
• DURRANT LG, MAXWELL-ARMSTRONG C, BUCKLEY D et al.: A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55. Clin. Cancer Res. (2000) 6:422–430.
   PubMed Web of Science ®Google Scholar
• •Anti-Id stimulates antitumour inflammatory responses allowing extravasation within tumour deposits of both helper T cells and NK cells.
   Google Scholar
• BHATTACHARYA-CHATTERJEE M, MUKERJEE S, BIDDLE W, FOON KA, KOHLER H: Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonicantigen. I Immunol (1990)145:2758–2765.
   PubMed Web of Science ®Google Scholar
• •Describes the generation and characterisation of a potential anti-Id vaccine, CeaVac.
   Google Scholar
• FOON KA, CHAKRABORTY M, JOHN WJ, SHERRATT A, KOHLER H, BHATTACHARYA-CHATTERJEE M: Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine., " Clin. Invest. (1995) 96:334–342.
   Google Scholar
• ••This is the first clinical trial demonstratingthe ability of anti-Id CeaVac to break immune tolerance to CEA in CEA-positive cancer patients.
   Google Scholar
• FOON KA, JOHN WJ, CHAKRABORTY M et al.: Clinical and immune responses in advanced colorectal cancer patients treated with anti- idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin. Cancer Res. (1997) 3:1267–1276.
   PubMed Web of Science ®Google Scholar
• FOON KA, JOHN WJ, CHAKRAGBORTY M et al: Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J. Clin. Oncol (1999) 17:2889–2895.
   PubMed Web of Science ®Google Scholar
• •Anti-Id immunisation induced both antibody and Thl CD4 T cell responses in patients which seemed to prolong relapse free and overall survival.
   Google Scholar
• CHATTERJEE SK, TRIPATHI PK, CHAKRABORTY M et al.: Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody. Cancer Res. (1998) 58:1217–1224.
   PubMed Web of Science ®Google Scholar
• ••Results suggest that linear peptides derivedfrom anti-Id CeaVac and nominal Ag CEA have amino acid sequence homology.
   Google Scholar
• MITTLEMAN A, CHEN ZJ, YANG H, WONG GY, FERRONE S: Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc. Nati Acad. ScL USA (1992) 89:455–470.
   Google Scholar
• ••An association was found betweendevelopment of HMW-MAA binding antianti-Id antibodies and statistically significant survival prolongation.
   Google Scholar
• MITTLEMAN A, CHEN ZJ, LIU CC, HIRAI S, FERRONE S: Kinetics of theimmune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse anti-idiotypic monoclonal antibody MK2-23. Cancer Res.(1994) 54:415–421.
   PubMed Web of Science ®Google Scholar
• ••A temporal association was found betweendevelopment of anti-HMVV-MAA antibodies and regression of metastatic lesions in a few patients.
   Google Scholar
• QUAN WD JR, DEAN GE, SPEARS L, MITCHELL M: Active specific immunotherapy of metastatic melanoma with an anti-idiotype vaccine: a Phase I/II trial of I-Mel-2 plus SAF-m. j Clin. Oncol (1997) 15:2103–2110.
   PubMed Web of Science ®Google Scholar
• •The development of anti-tumour antibodies after anti-Id immunisation was associated with disease stabilisation.
   Google Scholar
• SALEH MN, LALISAN DY JR,PRIDE MW et al: Immunologic response to the dual murine anti-Id vaccine Melimmune-1 and Melimmune-2 in patients with high-risk melanoma without evidence of systemic disease. J. Immunother. (1998) 21:379–388.
   PubMed Web of Science ®Google Scholar
• MCCAFFERY M, YAO TJ, WILLIAMS L, LIVINGSTON PO, HOUGHTON AN, CHAPMAN PB: Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin. Cancer Res. (1996) 2:679–686.
   PubMed Web of Science ®Google Scholar
• YAO TJ, MEYERS M,LIVINGSTON PO, HOUGHTON AN, CHAPMAN PB: Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin. Cancer Res. (1999) 5:77–81.
   PubMed Web of Science ®Google Scholar
• FOON KA, SEN G, HUTCHINS L et al.: Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin. Cancer Res. (1998) 4:1117–1124.
   PubMed Web of Science ®Google Scholar
• FOON KA, LUTZKYJ, BARAL RN et al: Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. j Clin. Oncol (2000) 18:376–384.
   PubMed Web of Science ®Google Scholar
• ••Results suggest that anti-IdTriGem
   Google Scholar
• ••mimicking GD2 may have a beneficial effect on the clinical course of melanoma.
   Google Scholar
• CHEUNG NV, GUO H, HELLER G, CHEUNG IY: Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-GD2 antibody therapy of stage 4 neuroblastoma. Clin. Cancer Res. (2000) 6:2653–2660.
   PubMed Web of Science ®Google Scholar
• ALFONSO M, DIAZ A,HERNANDEZ AM et al.: An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients.Irrnnunol. (2002) 168:2523–2529.
   Google Scholar
• GRANT SC, KRIS MG,HOUGHTON AN, CHAPMAN PB: Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotype antibody BEC2 plus Bacillus Calmette—Guerin. Clin. Cancer Res. (1999) 5:1319–1323.
   PubMed Web of Science ®Google Scholar
• REECE DE, FOON KA,BHATTACHARYA-CHATTERJEE M et al.: Use of the anti-idiotype antibody vaccine TriAb after autologous stem cell transplantation in patients with metastatic breast cancer. Bone Marrow Transplant (2000) 26:729–735.
   Google Scholar
• •Anti-Id vaccine was useful in some metastatic breast cancer patients in the transplant setting.
   Google Scholar
• MILLER RA, MALONEY DG,WARNKE R, LEVY R: Treatment of B-cell lymphoma with monoclonal anti-Id antibody. N Engl. J. Med. (1982) 306:517–522.
   PubMed Web of Science ®Google Scholar
• LEVY R, MILLER RA: Therapy of lymphoma directed at idiotypes. Nat. Cancer Inst. Monograph (1990) 10:61–68.
   Google Scholar
• LOWDER JN, MEEKER TC, CAMPBELL M et al.: Studies on B lymphoid tumors treated with monoclonal anti-Id antibodies: Correlation with clinical responses. Blood (1987) 69:199–210.
   PubMed Web of Science ®Google Scholar
• KWAK LW, CAMPBELL MJ, CZERWINSKI DK, HART S, MILLER RA, LEVY R: Induction of immune responses in patients with B-cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors. N Engl. J. Med. (1992) 327:1209–1238.
   PubMed Web of Science ®Google Scholar
• HSU FJ, CASPAR CB, CZERWINSKI D et al.: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma — long term results of a clinical trial. Blood(1997) 89:3129–3135.
   PubMed Web of Science ®Google Scholar
• RUFFINI PA, NEELAPU SS, KWAK LW, BRAGYN A: Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haernatol (2002) 87:989–1001.
   Google Scholar
• PRIDE MW, SHI H, ANCHIN JM, THANAVALA Y: Molecular mimicry of hepatitis B surface antigen by an anti-idiotype-derived synthetic peptide. Proc. Natl. Acad. Sci. USA (1992) 89:11900–11904.
   PubMed Web of Science ®Google Scholar
• •Linear peptides derived from hepatitis B surface antigen and anti-Id hybridoma share amino acid sequence homology.
   Google Scholar
• SPENDLOVE I, LI L, POTTER V,CHRISTIANSEN D, LOVELAND BE, DURRANT LG: A therapeutic human anti—idiotypic antibody mimics CD55 in three distinct regions. Ear: J Innnunol. (2000) 30:2944–2953.
   PubMed Web of Science ®Google Scholar
• ••Cloning of both antigen and anti-Id showsthe molecular basis of their mimicry.
   Google Scholar
• SCHUURHUIS DH, IOAN-FACSINAY A, NAGELKERKEN B et al.: Antigen-antibody immune complexes empower dendritic cells to efficiently prime CD8+ CTL responses in vivo. J. Innnunol. (2002) 168:2240–2246.
   Google Scholar
• FOON KA, BHATTACHARYA-CHATTERJEE M: Idiotype vaccines in the clinic. Nat. Med. (1998) 4:870.
   PubMed Web of Science ®Google Scholar
• FOON KA, BHATTACHARYA-CHATTERJEE M: The biology behind: are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res. (2001) 7:1112–1115.
   Google Scholar